Therefore, PEG-asparaginase may have the same efficacy as E. coli-asparaginase and be safely used as another choice of asparaginase in adults with standard-risk ALL given its more rapid clearance of lymphoblasts on day 14, reduced incidence of allergy, and similar long-term outcome and convenience. The gene discussed is ASPG; the disease is allergic disease.